A couple things… he has used it enough for the 4 years at least… he had the benefits for his age and could stop cold turkey. All the possible benefits are still in effect.
He can say he stopped… but in reality- keep using. Who knows.
He was very pro-rapamycin for alzheimer’s.
Matt Kaeberlein stopping would have me take pause… and want to know why.
I have not watched yet, but this was along my thinking. I guess he has been taking it for close to a decade, and the guy is only 52, so he has plenty of time to start up again.
Also, I am not sure I can trust that he really stopped. Maybe, maybe not. He has said he doesn’t want to have a rapamycin mill, but I imagine most patients say I want some because you are taking it, so it must be good.
It was just last week where I heard him say it increases longevity in everything it’s been tested in, so that doesn’t sound like a guy who stops?
But also, if he truly thinks every single drop of protein/muscle matters at the detriment of everything else, which he kinda does, then rapa will contribute to a couple of days where he isn’t maxing out his muscle building potential. And if he is telling the world eat all the protein you can get your hands on, including what I sell, I was always bothered that was easy for him to say while he is offsetting some of it while taking rapa, so this makes his message better, IMO
I’ll also add, in my emails from him, they are advertising to get new docs on board, so it seems he is about to create something much bigger. This might also be contributing to this decision.
EDIT: forget everything I just said. I read the article and it says he stopped rapa for now due to mouth sores. That is not someone trying to shy away from the drug.
He’s planning an app that will go mainstream, available on every phone in the world.
In the full 60 minutes video they just say he stopped taking it for now because of mouth sores.
Indeed… and I might sign up too! I’m interested in everything he has to say if it doesn’t involve protein 
This is what I was referring to… I can’t imagine putting this in his mass emails if he is only adding 1 or 2 docs to his practice?
You can see Peter Attia’s team here (at that point in time): "Early" Longevity Program by Peter Attia Launches - #62 by RapAdmin
Your post lowered my epigenetic methylation age by 1.2 years (ci ±10 years). Keep posting please.
So after 4 plus years of using rapamycin - it’s the mouth sores… ?!?
David Sabatini told him how to eliminate that with a simple mouth wash in their everything rapamycin podcast with Matt Kaeberlein months ago.
I have never had a mouth sore once… so it had no interest to me.
Whatever.
I also call BS
I saw that podcast, too. And yeah, the guy who would fast for one week a month who has to stop due to an occasional mouth sore … I guess he has a great bridge to sell me, too
In Peter Attia’s recent interview, Eric Verdin shared his thoughts on the limitations of mouse models when it comes to the longevity quotient, which PA found compelling. If PA has indeed stopped taking Rapamycin, it might suggest he’s increasingly convinced that evolutionary pathways in humans are already optimized in ways that Rapamycin targets in rodents. I don’t think mouth sores are the reason behind his decision.
Agreed… and the transcription - article says he’s stopped for now… that doesn’t sound like stopped forever.
That argument - already optimized pathways - is an interesting one. It doesn’t mean that interventions to extend human lifespan don’t or can’t exist in principle. It just means that the pathways that result in shorter lifespans in animal models, such as rodents and species experiencing high predation, promoting early fecundity and reproduction, are optimized in humans. You might call them low hanging fruit. This would imply that those interventions that impact these “rodent” pathways may not work in humans, as that’s already taken care of by evolution. The same argument was also put forward wrt. CR. There may be something to that argument. But, I would not make a blanket statement wrt. ALL longevity interventions in humans, because not all of those map to rodents. There may - and certainly are - longevity pathways that can be impacted in humans. Otherwise we’d have to posit that humans are as longevity optimized as possible, which seems unlikely. There were simply no evolutionary pressures to make humans live longer, and we can try to fill in those gaps with interventions (drugs, but ultimately by design change through genetic engineering).
In any case, I think it’s entirely legitimate to ask if rapamycin buys humans anything at all, whether in healthspan or lifespan. I’m gambling that yes, because the pathway that rapamycin works on is such a fundamental one, and is preserved throughout the evolutionary tree. Unless you believe that humans reached an “all longevity pathways optimization” peak such that it’s impossible to improve upon - which I think is unlikely - then rapamycin has a good enough (for me) chance to work somewhat in humans. Humans are mammals. Are humans the peak longevity achievement for the mammalian physiology? No. There are whales that live longer. I don’t bring up non-mammals, such as sharks, fish, reptiles, mollusks etc. because the physiology is just too different. But 200 year old whales tell me that the mammalian physiology has inherent in it greater longevity capacity than the human 120-130. We can look at it from the whale point of view: “gee, rapamycin works in humans, because they have sloppy longevity pathways, but rapamycin will not work on us, because we, at 200+ year lifespans already have all pathways optimized, so fellow whales, we reject rapamycin as unlikely to work as it works in humans”. And here, I see my personal gamble on rapamycin as reasonable (for me and my risk tolerance).
Of course, it is also necessary to perform a cost/benefit analysis. There are costs to rapamycin that we know of: possibly lesser muscle hypertrophy, immune suppression, mouth sores, bacterial infection vulnerability and so on. Some of these might be mitigated through dosing protocols and polypharmacy. There are of course unknown risks. But on balance my risk tolerance results in a YES to rapamycin for me and my situation. YMMV.
When you see surveys and studies, do you ever think to yourself, “Fu*k me, nobody ever asked me”?
As I have stated before, I don’t expect anyone who is healthy and young to feel any subjective benefits from taking rapamycin. Like an oil change for your car, you see zero immediate effect, but you know long-term, the motor will last longer if you do it.
The positive effects are more difficult to measure with routine lab checks; the negative effects are easier to measure, such as increases in lipids, glucose levels, etc.
So, has anyone published even an observational study of 75+ year olds taking weekly, medium-to-high doses for several years? I think not. Again, no one asked me (except members of the forum).
I felt immediate subjective benefits, such as a dramatic reduction in age-related pains, actinic keratosis, and essential tremors. Rapamycin has slowed down sarcopenia to the point that I am finding the progression too small to measure, as is any ocular degeneration.
Will rapamycin extend my life beyond my genetic programming fate? I don’t know, but I think it will. I am absolutely positive it extends median life spans and health spans.
Anyone who ignores the mammalian animal studies that almost universally show it extends life spans does so at their own peril. No one has presented any compelling evidence that humans are the exception.
If Rapamycin works for yeast, flies, worms, crickets, mice, dogs, marmosets and humans (measures of health such as immune system and strength) with a 99% success rate over 164 studies, I think that’s enough proof for me.
The last bit of proof will come when @desertshores hits 150. That’ll cinch it for me. 
Yes - I think the marmoset results confirm that the leap to primates for rapamycin is effective. So I’m pretty optimistic that we’ll get some benefits from rapamycin, though probably not the 30% we see in mice (at least with Rapamycin alone).
I think it’s possible to get 15% if you pair Rapamycin with an SGLT2I/Acarbose/Metformin. For someone who would normally live to 95, that would take them to 110. That’s very respectable and reasonable.
Good point. Pairing some drugs results in increased lifespan in animal models beyond the increase of each separately. That includes drugs that alone may not extend lifespan, such as metformin or simvastatin.
Frankly, with the drugs available presently for humans, I think polypharmacy is even more important than in animal models. And individualized precision medicine is especially important. At present, for me, it’s rapamycin, empagliflozin, telmisartan, pitavastatin, bempedoic acid + ezetimibe, and possibly pioglitazone in the near future (still doing literature research on that). Each of us has a unique profile of strengths and vulnerabilities, and addressing our individual weakest links should give us the greatest returns in health/lifespan.
That’s what most, if not everymember of the forum, is doing. 
I’m not trying to argue against Rapa, just saying there is a legitimate argument for not taking it. Everyone who gets positive benefits from Rapa is unfortunately just an n of 1. Medical treatment requires solid scientific studies.
Even if we agree that there is evidence that Rapa is beneficial, would it still be beneficial on top of maximizing all the other beneficial activities?
Marmosets in captivity have a significantly longer lifespan than those in the wild. They get as much sleep and food as they need. Their food is probably nutritious, as I assume they are being fed vegetables instead of pizza, and a nutritionist probably plans their diet. Their stress levels are probably low (maybe too low?) They may even get blood tests regularly by a vet to measure for deficiencies, like normal zoo animals do. The only area where they may not achieve optimal results is exercise. Given all that, Rapamycin extends their lifespan 15% on a near-optimal lifestyle.
Now, let’s take your average American. Diet is crap. Stress is high. Not enough sleep. Obese. Not enough exercise. They rarely go to a doctor for prevention. If anything, Rapamycin would probably help humans more than your average marmoset who leads a pretty optimal lifestyle, IMHO. This is why your typical American dies at 77 and your typical wealthy American dies at 95. As for the rest of us here, we probably don’t live as optimal a lifestyle as the captive marmoset, so why wouldn’t Rapamycin help us? I’m betting it will.
I’d wager that a typical wealthy American on Rapamycin (plus SGLT2I/acarbose/Metformin) can gain an extra 14 years and live to 109 on average with the health of a 95-year-old. Here’s hoping I can celebrate my father’s 110th birthday with him.
